Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

Similar Items

• In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole
  od: Pfaller, M. A., i dr.
  Izdano: (1998)
• Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp.
  od: Law, D, i dr.
  Izdano: (1997)
• In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans
  od: Pfaller, M. A., i dr.
  Izdano: (2001)
• In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida
  od: Cacciapuoti, Anthony, i dr.
  Izdano: (2000)
• In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
  od: Galgiani, J N, i dr.
  Izdano: (1997)